ICER publishes final evidence report on fezolinetant for vasomotor symptoms associated with menopause

23 January 2023 - Independent appraisal committee voted that evidence is not yet adequate to demonstrate a net health benefit ...

Read more →

Public Summary Documents – September 2022 PBAC meeting

13 January 2023 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the September 2022 PBAC ...

Read more →

ICER publishes final evidence report on gene therapies for haemophilia A and B

22 December 2022 - Fair pricing benchmarks suggest upper bounds for price of Roctavian at approximately $1.9 million and for Hemgenix ...

Read more →

Final report for the post-market review of medicines for smoking cessation and review outcomes

22 December 2022 - The final report for the post-market review of medicines for smoking cessation is now available. The ...

Read more →

ICER publishes evidence report on treatments for multiple sclerosis

21 December 2022 - Evidence is rated as insufficient to differentiate the net health benefit between ublituximab and other monoclonal antibodies; ...

Read more →

PBS Expenditure and Prescriptions Report (2021-22)

21 December 2022 - The PBS Expenditure and Prescriptions Report 1 July 2021 to 30 June 2022 is now available. ...

Read more →

ICER publishes evidence report on fezolinetant for vasomotor symptoms associated with menopause

1 December 2022 - Evidence is rated as promising but inconclusive to determine whether fezolinetant provides a net health benefit for ...

Read more →

PBAC Public Summary Document (November 2022)

18 November 2022 - The Public Summary Documents for the Review of the base-case discount rate in the PBAC Guidelines from ...

Read more →

Public Summary Documents (first time decisions not to recommend and deferrals) - July 2022 PBAC meeting

11 November 2022 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the July 2022 PBAC ...

Read more →

Outcome statement - September 2022 DUSC meeting

3 November 2022 - The outcome statement from the September 2022 DUSC meeting is now available. ...

Read more →

Public Summary Documents – July 2022 PBAC meeting

28 October 2022 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the July 2022 PBAC ...

Read more →

DUSC utilisation analysis public release documents (October 2022)

25 October 2022 - The utilisation analysis public release documents from the June 2022 DUSC meeting are now available. ...

Read more →

ICER publishes final evidence report and policy recommendations on treatments for obesity management

20 October 2022 - Independent appraisal committee voted that evidence is adequate to demonstrate that semaglutide provides a net health benefit ...

Read more →

ICER releases draft evidence report on treatments for multiple sclerosis

17 October 2022 - Public comment period now open until 11 November 2022; requests to make oral comment during public ...

Read more →

HARmonized protocol template to enhance reproducibility of hypothesis evaluating real world evidence studies on treatment effects: a good practices report of a joint ISPE/ISPOR Task Force

12 October 2022 - Ambiguity in communication of key study parameters limits the utility of real-world evidence studies in health care ...

Read more →